| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 42
| Issue : 4 | Page : 234-240 |
|
|
Estimating second malignancy risk in intensity-modulated radiotherapy and volumetric-modulated arc therapy using a mechanistic radiobiological model in radiotherapy for carcinoma of left breast
Vasanthan Sakthivel1, Ganesh Kadirampatti Mani2, Sunil Mani3, Raghavendiran Boopathy3, Jothybasu Selvaraj4
1 Research and Development Centre, Bharathiar University, Coimbatore, Tamil Nadu, India; Advanced Medical Physics, Houston, Texas, USA, India
2 Research and Development Centre, Bharathiar University, Coimbatore, Tamil Nadu; Department of Radiation Physics, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
3 Advanced Medical Physics, Houston, Texas, USA
4 Medical Physics and Radiation Engineering, The Canberra Hospital, Canberra, Australia
Correspondence Address:
Vasanthan Sakthivel
Research and Development Centre, Bharathiar University, Coimbatore, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jmp.JMP_89_17
|
|
|
Objectives: The aim of this study is to estimate second cancer risk (SCR) in intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) using a mechanistic radiobiological model. The model also takes into account patient age at exposure and the gender-specific correction factors of SCR. Materials and Methods: Fifty IMRT and VMAT plans were selected for the study. Monte Carlo-based dose calculation engine was used for dose calculation. Appropriate model parameters were taken from the literature for the mechanistic model to calculate excess absolute risk (EAR), lifetime attributable risk, integral dose and relative risk (RR) for lungs, contralateral breast, heart, and spinal cord. Results: The mean monitor unit (MU) in IMRT and VMAT plans were 751.1 ± 133.3 and 1004.8 ± 180, respectively, for IMRT and VMAT. The mean EAR values with age correction were 44.6 ± 11.9, 11.2 ± 6.4, 5.4 ± 4.0, 1.4 ± 0.5, and 0.3 ± 0.2 for left lung, right lung, contralateral breast, heart, and spinal cord, respectively, for the IMRT treatments and 54.6 ± 20.6, 30.2 ± 12.0, 13.8 ± 8.6, 1.6 ± 0.6, and 0.9 ± 0.5 for the VMAT treatments in units of 10,000 PY. The RR of 6.7% and 9.1%, respectively, for IMRT and VMAT found in our study using computational models is in close comparison with the value reported in a large epidemiological breast cancer study. Conclusions: VMAT plans had a higher risk of developing second malignancy in lung, contralateral breast, heart, and cord compared to IMRT plans. However, the increase in risk was found to be marginal compared to IMRT. Incorporating the age correction factor decreased the risk of contralateral breast SCR. No strong correlation was found between EAR and MU. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
|
|
| Article Access Statistics | | | Viewed | 2545 | | | Printed | 100 | | | Emailed | 0 | | | PDF Downloaded | 240 | | | Comments | [Add] | | | Cited by others | 8 | | |
|
|
